Background-We prospectively evaluated the relationships between fasting plasma levels of vitamin B 6 , as pyridoxal phosphate, and subsequent myocardial infarction risk in women. Methods and Results-Among 32 826 women who provided blood samples between 1989 and 1990 (27% of the original 1976 cohort), 239 were diagnosed with incident myocardial infarction (fatal and nonfatal) after blood collection but before July 1998. Of these women, 144 had provided a sample after fasting Ͼ10 hours. Cases were matched 1:2 by age, cigarette smoking status, and month of and fasting status at the time of blood collection with controls from the same cohort. Conditional logistic regression was used to adjust for potential confounders, including traditional coronary risk factors, anthropometric factors, dietary intake, and selected biomarkers. Median age at blood collection was 63 years. Plasma levels of pyridoxal phosphate were inversely associated with risk of myocardial infarction; the multivariableadjusted rate ratio for the highest compared with the lowest quartiles (Ͼ70 versus Ͻ27.9 pmol/mL) was 0.22 (95% confidence interval, 0.09 to 0.55; P for trendϭ0.05). The association varied by age: among women who were Ͻ60 years of age at blood sampling, the rate ratio comparing the highest and lowest quartiles was 0.05 (95% confidence interval, 0.004 to 0.61), whereas among older women, the corresponding rate ratio was 0.36 (95% confidence interval, 0.13 to 1.02). Conclusions-Fasting plasma concentration of pyridoxal phosphate was inversely associated with myocardial infarction risk, an effect that was in part independent of dietary B 6 intake. In addition to dietary vitamin B 6 intake, there are other determinants of plasma vitamin B 6 status, and these factors warrant further research. (Circulation. 2009;120:649-655.)
C oronary artery disease remains the leading cause of mortality among postmenopausal women in the United States. 1, 2 Several epidemiological studies have suggested that vitamin B 6 may be important in the prevention of coronary artery disease. 3, 4 Vitamin B 6 is widely involved in 1-carbon transfer 5 and is a cofactor for Ͼ100 human enzymes 6 that are essential in amino acid metabolism (including the homocysteine-cystathionine-cysteine conversion), carbohydrate and lipid metabolism, and neurotransmitter production. In addition to its role in macronutrient metabolism, vitamin B 6 is important in steroid receptor interactions, 7 immune response, 8 and mineral transport across cell membranes. 9 In circulation, it exists mainly as pyridoxal 5Ј phosphate (PLP). One published study found that plasma concentrations of PLP are inversely associated with C-reactive protein (CRP) concentration independently of plasma total homocysteine. Another epidemiological study has demonstrated that dietary vitamin B 6 is inversely related to the risk of myocardial infarction (MI). 3 Three studies have evaluated the relationship between plasma PLP and heart disease. One cohort study in men did not evaluate postfasting PLP 10 ; another was a cross-sectional study that looked at the relationship between fasting PLP and angiographically proven coronary artery disease. 11 Only 1 prospective cohort study evaluated the relationship between fasting PLP and MI in middle-aged adults. 2 However, that study also included "silent MI" defined by ECG only and coronary revascularization.
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Apart from dietary intake, plasma concentration of PLP likely depends on variability in absorption by the gastrointestinal tract, its uptake in the liver, its activation and deactivation by various metabolic processes, and its excretion by the kidneys. So far, these factors have not been systematically studied in epidemiological studies. Plasma concentration of PLP is sensitive to feeding status 12 and decreases after glucose ingestion. 13 Using prospectively collected samples in a nested casecontrol design within the Nurses' Health Study cohort, we sought to answer 2 primary questions: What are the major determinants of the fasting plasma concentration of PLP in women, and what is the relationship between plasma levels of PLP in the fasting state and subsequent risk of MI? Secondary subgroup analyses were carried out to examine the extent to which the effect of plasma PLP varied with fasting homocysteine concentration, renal function, body mass index (BMI), alcohol use, consumption of multivitamin supplements, dietary folate intake, or age at blood sampling. Because plasma PLP may decrease in response to MI, 12, 14 we also conducted a sensitivity analysis after excluding case-control sets in which MI occurred within 2 years of blood sampling.
Methods

Study Population
The Nurses' Health Study cohort was established in 1976 when 121 700 female registered nurses 30 to 55 years of age completed a mailed questionnaire to study the relationship between diet and lifestyle and subsequent disease. The cohort continues to be followed up every 2 years by questionnaire to update exposure status and to identify cases of newly diagnosed disease. Data have been collected on many coronary artery disease risk factors, including height, weight, cigarette smoking, alcohol use, physical activity, age at menopause, postmenopausal hormone use, diagnosis of hypertension and diabetes mellitus, history of aspirin use, and parental family history of MI. BMI was calculated by dividing the most recent weight before blood collection by the square of height reported in 1976.
Dietary information was collected by food frequency questionnaires that had been completed by the participants in 1980, 1984, and 1986. These questionnaires, which assessed the average consumption of a specific amount of each food during the past year, allowed 9 frequency responses, ranging from never to Ն6 times per day. Nutrient intake per day was calculated by multiplying the frequency response by the nutrient content of the specified portion sizes. Total alcohol intake per day was calculated as the sum of the alcohol content contributed from beer, wine, and liquor, assuming 12.8 g ethanol for 360 mL (12 oz) beer, 11.0 g for 120 mL (4 oz) wine, and 14.0 g for 45 mL (1.5 oz) liquor. Duration, brand, and type of multivitamin supplement use were updated in the biennial questionnaires or the food frequency questionnaires, and a comprehensive database on the vitamin content of the multivitamin preparations was developed. The validity and reliability of the food frequency questionnaires used in the Nurses' Health Study have been described previously. [15] [16] [17] From 1989 through 1990, blood samples were collected from 32 826 cohort members (27% of the original cohort) who were then 43 to 69 years of age. Participants who provided blood samples were similar to those who did not. Details of the blood collection methods have been published previously. 18 Briefly, each woman arranged to have her blood drawn and then shipped, via overnight courier with an ice pack, to our laboratory, where it was processed and separated into plasma, red blood cells, and white blood cell components. Within 24 to 36 hours of being drawn, 97% of the samples were received in our laboratory. Since collection, samples have been archived at Ϫ130°C or colder in continuously monitored liquid nitrogen freezers. As of 1998, follow-up of women who provided blood samples was 99.8% complete.
We included as cases those women who provided a blood sample after fasting Ն10 hours, reported no MI before blood collection, and were diagnosed with MI after blood collection but before June 1, 1998. Overall, 144 cases of MI (21 fatal) with adequate plasma were identified. For all cases of MI, we requested hospital records (We could not obtain records for 3 cases but retained all cases for analysis). MI was classified as confirmed if symptoms met the criteria of the World Health Organization (typical symptoms and either diagnostic ECG changes or elevated cardiac enzymes). Controls who fasted Ն10 hours before providing a blood sample were on average 2 years older than those who did not fast (Pϭ0.001), but the 2 groups were similar in other respects.
The median time from blood collection to diagnosis was 48 months (10th to 90th percentiles, 16 to 91 months). Two control subjects who did not have a diagnosis of MI at the time of the case's diagnosis were selected at random, matched to the case subject by age (Ϯ2 years), cigarette smoking status (current, past, and never smoker), month of blood collection, and fasting status at the time of blood collection (Ն10 hours since a meal). Eighty-one percent of control matches were exact; the most relaxed match was within Ϯ3 years of age and within Ϯ6 months of blood collection. The matched sets were analyzed together. The study was approved by the Committee on the Use of Human Subjects in Research at the Brigham and Women's Hospital. All subjects gave their informed consent to participate.
Laboratory Analyses
Plasma levels of PLP were determined by an enzymatic procedure using radioactive tyrosine and the apoenzyme tyrosine decarboxylase 19, 20 at the Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging at Tufts University. During the assay process, we interspersed replicate plasma samples, which were labeled to preclude their identification by the laboratory, to assess laboratory precision. The intra-assay coefficient of variation for plasma PLP was 8.9%.
Creatinine was measured with a modified Jaffe method. The intra-assay coefficient of variation was 12.8%. We used a modified version of the Cockcroft-Gault formula to estimate creatinine clearance (CrCl). [21] [22] [23] This formula, based on fat-free body mass, has the advantage of attenuating the overestimation of CrCl in obese individuals with the Cockcroft-Gault equation while providing similar results in average-weight women. 22 The formula for women is as follows: (146Ϫage)ϫ[(0.287ϫweight)ϩ(9.74ϫheight
2 )]/(60ϫcreat-inine), where age is measured in years, weight is measured in kilograms, height is measured in meters, and creatinine is measured in milligrams per deciliter. The unit for CrCl is milliliter per minute. This formula has been validated compared with measured CrCl. 22 Plasma homocysteine concentrations were measured with highperformance liquid chromatography using fluorescence detection at the Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging at Tufts University. 19, 24 The intra-assay coefficient of variation for plasma total homocysteine was 7.5%. Total cholesterol was measured enzymatically 25 with an intra-assay coefficient of variation of 1.7%. High-density lipoprotein (HDL) cholesterol was measured with a Hitachi 911 (Roche, Basel, Switzerland) analyzer, 26 with an intra-assay coefficient of variation of 2.5%. CRP was determined with a high-sensitivity immunoturbidimetric assay on a Hitachi 911 analyzer, with an intra-assay coefficient of variation of 1.4%.
All matched case-control blood samples were handled identically and together, handled in the same batch, and assayed in the same analytical run. All assays were conducted by laboratory personnel without knowledge of the case-control status of the samples.
Data Analysis
Percentiles were calculated for continuous variables in cases and in controls as 2 separate groups. We estimated probability values to test the covariates for differences between cases and controls by conducting individual conditional logistic regression models for each variable, with continuous variables modeled as linear predictors and categorical variables modeled as indicator functions, and the log odds of MI as the outcome.
We estimated Spearman correlation coefficients between continuous variables and plasma PLP. Among the samples provided by controls, we conducted linear regression analyses, with the natural logarithm of plasma PLP as the response variable, to evaluate the relationship of fasting PLP concentration to quarters of the continuous variables and indicator functions of the categorical variables while controlling for an indicator function of blood analysis batch. The continuous variables were age; plasma total homocysteine; CrCl; plasma CRP; ratio of total to HDL cholesterol; physical activity; BMI; dietary intake of energy-adjusted total protein, total calories, vitamin B 6 , folate, vitamin B 12 , vitamin B 1 , vitamin B 2 , vitamin C, and magnesium; servings of breakfast cereal; and alcohol. The categorical variables were menopausal status (premenopausal, postmenopausal, unknown menopausal status), current postmenopausal hormone use at blood collection, a personal history of being diagnosed with diabetes mellitus, a personal history of being diagnosed with hypertension, parental history of MI before 60 years of age, cigarette smoking status (never smoker, past smoker, or current smoker of Ͻ15, 15 to 24, and Ͼ24 cigarettes per day), a history of hypercholesterolemia, and a history of aspirin use (use for Ͼ14 or 1 to 14 d/mo and no aspirin use). Because little is known about the predictors of plasma PLP, we used a modified backward-stepwise MET indicates metabolic equivalent. *There were 144 cases and 258 controls. Median age at diagnosis was 67.0 years (10th and 90th percentiles, 55.4 and 73.7 years). Median time from blood sample to diagnosis was 4.1 years (10th and 90th percentiles, 1.25 and 7.6). Waist-to-hip ratio was available for 101 cases and 178 controls. Information was available for the other covariates in Ͼ95% of study participants.
†Estimated by conditional logistic regression.
procedure to determine which variables should remain in the model as judged by statistical significance (PϽ0.05) of the F test 27 (PϽ0.05). The initial model included all of the nonbiomarker variables listed above and CrCl; and variables were removed individually in order from largest to smallest P value on the F test until the only variables remaining were statistically significant predictors. All 3 indicators for each continuous variable were considered 1 variable. The previously removed variables were then individually returned to determine statistical significance in the modified model, at which point, all previously removed variables were returned and the backward elimination was repeated. This procedure was repeated iteratively until no added or removed variable resulted in statistically significant changes to the model, the "final model." The relationships of biomarkers to plasma PLP were determined in the multivariable model by individually adding the respective variable to this final model. Conditional logistic regression was used to estimate odds ratios between quarters of plasma PLP concentration and risk of MI. These odds ratios were taken as direct estimates 28 of rate ratios (RRs) and 95% confidence intervals (CIs). 29 We additionally controlled for potential confounders that were not part of the matching scheme. To control more appropriately for confounding and other covariation by continuous variables, natural cubic splines 28,29 with 4 df were used to smooth the relationships with the log-odds of MI. Physical activity in metabolic equivalent hours per week in 1988 was entered into the regression models as indicator functions of the quarters because natural cubic splines did not determine a good fit for this variable. Indicator functions of the categorical covariates were used. We estimated the following models: a model that controls for matching factors only; a model that controls for conventional nonbiomarker risk factors for MI (considered the definitive model); a model that additionally controls for CrCl, the ratio of plasma total to HDL cholesterol, and plasma high-sensitivity CRP; and a model that controls for predictors (including dietary pyridoxine and folate) of plasma PLP. There were very few missing values in the covariates physical activity, CRP, creatinine, and ratio of total to HDL cholesterol (all Ͻ4%); thus, medians were used for imputation. Tests for interaction were done by including product terms between indicator functions of halves of the respective variable and indicator functions of quarters of PLP in the definitive model above.
We conducted tests for trend by modeling the biomarker level as a linear continuous covariate and calculating a Wald statistic. 29 All P values were based on 2-sided tests. The software used for statistical analysis were SAS release 9.1 30 and S-plus version 8. 31 The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written. Table 1 shows the distribution of risk factors for MI at the time of blood sampling among cases and matched controls. As expected, average BMI, total cholesterol, CRP, histories of diabetes mellitus, hypertension, and having had a parent with early MI were all higher in cases. Similarly, the levels of alcohol consumption and plasma HDL cholesterol were lower in those who later developed MI compared with controls.
Results
Plasma concentrations of PLP were inversely correlated with estimated CrCl and BMI and directly correlated with dietary intake of vitamin B 6 ( Table 2) . Our model that included dietary B 6 , folate, multivitamin supplements, BMI, and estimated CrCl explained 30.2% of the variation in plasma PLP. After adjustment for estimated CrCl, BMI, dietary intake of vitamin B 6 , and folate, plasma PLP also was inversely correlated with plasma homocysteine. Plasma concentration of PLP was not predicted by age, menopausal status, use of postmenopausal hormones, protein intake, total caloric intake, physical activity, alcohol consumption, or ratio of plasma total to HDL cholesterol; by history of hypertension, diabetes mellitus, or cigarette smoking; or by parental history of MI before 60 years of age (data not shown).
Fasting concentrations of PLP were significantly inversely associated with subsequent risk of MI (RR for top versus bottom quartile , 0.22; 95% CI, 0.09 to 0.55; P for linear trendϭ0.047; Table 3 and the Figure) . The effect of adding PLP to a conditional logistic regression model with conventional MI risk factors was statistically significant ( 2 3df ϭ15.8, Pϭ0.001). To examine the monotonicity of the relationship between the log rate of MI and plasma PLP, we examined the relationship with 20-pmol/mL PLP categories. Compared with plasma PLP Ͻ20 pmol/mL, concentrations of 20 to 39, 40 to 59, 60 to 79, 80 to 99, 100 to 119, and Ն120 pmol/mL were associated with MI with estimated RRs of 0.4, 0.5, 0.3, 0.3, 0.1, and 0.1, respectively. The shape and magnitude of the relationships changed little with the addition of the ratio of plasma total to HDL cholesterol, CRP, homocysteine, or dietary determinants of plasma PLP (dietary pyridoxine and folate) to the regression model. When we excluded cases that occurred within 2 years of blood sampling, the size of the relationship between fasting PLP and MI was little changed (RR for top versus bottom quartile, 0.26; 95% CI, 0.10 to 0.76; P for linear trendϭ0.09).
The relationship between PLP and risk of MI appeared to vary with age ( 2 3df ϭ11.0, Pϭ0.012). The effect of plasma PLP was stronger among women who were Ͻ60 years of age at blood sampling (RR for top versus bottom quarter, 0.05; 95% CI, 0.004 to 0.61) compared with older women (RR for top versus bottom quarter, 0.36; 95% CI, 0.13 to 1.02). The relationship between plasma PLP and risk of MI was similar among those who consumed multivitamin supplements and those who did not. There was no statistically significant effect modification by dietary folate intake, alcohol use (any use versus no use), BMI Ͼ25 versus Ͼ25 kg/m 2 , estimated CrCl, or plasma total homocysteine.
Discussion
The main finding of the study is that a low plasma concentration of PLP is associated with increased rate of MI among predominantly postmenopausal women. This was demonstrated by the statistically and clinically significant lower incidence of MI associated with higher PLP concentration ( Table 3 and the Figure) , even after adjustment for pyridoxine and folate intake. Although there was a steep decline in MI risk for PLP concentrations Ͼ20 pmol/mL relative to lower concentrations, risk continued to decline with higher levels. The effect was more pronounced in younger compared with older women. We also found that estimated CrCl, dietary vitamin B 6 intake, dietary folate intake, and BMI were statistically significant predictors of fasting plasma levels of PLP. The fasting concentration of PLP also was inversely correlated with total homocysteine.
The finding that plasma concentrations of PLP is inversely related to risk of MI is consistent with the knowledge of the important role of vitamin B 6 in protein metabolism, including homocysteine metabolism, and its likely effects on mineral transport across cell membranes. 9 These results are in agreement with those of other epidemiological studies that have shown that dietary vitamin B 6 and plasma PLP are inversely related to the risk of MI 3 and the risk of coronary artery disease. 2 This is consistent with the role of PLP as a cofactor in the conversion of homocysteine to cysteine in the transsulfuration pathway. Although 2 prospective studies have now shown that low fasting plasma PLP is inversely associated with the risk of MI, randomized controlled trials that have studied homocysteine lowering with folic acid, vitamin B 6 , and vitamin B 12 found that this therapy, although successful in reducing homocysteine, did not reduce the incidence of the combined outcome of MI, stroke, and cardiovascular death. [32] [33] [34] [35] Vitamin B 6 supplementation alone also was not successful in reducing the risk of MI. 33 This conflict may be resolved if it is found that factors other than diet that control plasma PLP are more important in preventing MI. The finding that the plasma concentration of PLP is positively correlated with dietary intake of vitamin B 6 is consistent with a number of studies that demonstrated that dietary supplementation of vitamin B 6 results in an increase in plasma concentration. 34, 36 The positive association between dietary folate and plasma PLP concentration may reflect a vitamin B 6 -sparing effect of increased folate by its reduction of the flux of homocysteine via the transsulfuration pathway. The negative correlation between estimated CrCl and plasma levels of PLP is consistent with the fact that vitamin B 6 is almost completely excreted by the kidneys. 37 It is unclear whether the negative correlation between BMI and plasma PLP is due to a direct effect of BMI on vitamin B 6 . Although animal studies suggest that high-protein diets increase requirements for vitamin B 6 , we did not find a relationship between protein intake and plasma PLP. Chronic alcohol use results in increased alkaline phosphatase 38 and thus may affect the concentration of plasma PLP, 39 but we did not find significant relationships in this data set. Older individuals have been found to have lower PLP concentrations compared with the young in another study, 40 but this was not the case in this study. This may be related to the fact all the women in this study were Ͼ40 years of age and thus there may not have been a sufficient variation in age. The fact that our linear regression model explained only 30% of the variation in plasma PLP reinforces the fact that there are important determinants not accounted for by the measured variables. This also helps to explain our finding that the relationship between plasma PLP and MI risk was little affected by the inclusion of measured determinants of PLP concentration such as dietary pyridoxine in the regression model (Table 3) .
The concentration of PLP in this study was greater than that in the 1 other prospective study that assessed fasting levels of PLP. 2 The geometric mean of PLP concentration among controls in this study was 45.6 pmol/mL. The geometric mean among controls in that study, which included both men and women, was 31.5 pmol/mL.
To the best of our knowledge, this is the first prospective study that has looked specifically at the relationship of fasting levels of PLP with MI in predominantly postmenopausal women. The major strengths of this study are its prospective design and its careful control of confounding factors. In addition, we were able to reduce measurement error in PLP and other plasma covariates by focusing on those women who had provided blood after fasting for Ն10 hours. However, given the observational nature of the study, we cannot be sure that all unknown confounders have been adequately controlled. Although this study has a sufficient sample size to examine the primary questions, it is not large enough to examine the interactions with certainty.
Conclusions
Our investigation revealed that a lower fasting concentration of PLP is significantly associated with an increased risk of MI in predominantly postmenopausal women, a relationship that may be causal. We also found that it is inversely correlated with a measure of renal function and with BMI. Future studies are needed to better understand both dietary and nondietary determinants of plasma and tissue vitamin B 6 status and their role in the prevention of MI and other chronic diseases.
